Related Experiment Video
Updated: Mar 20, 2026
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
3.0K
Interleukin-1 Inhibition in Behçet's disease
The Israel Medical Association Journal : IMAJ
|May 28, 2016
Summary
Behçet's disease (BD) is now viewed as a hybrid autoimmune and autoinflammatory syndrome. Interleukin-1 (IL-1) inhibition shows promise for treatment-resistant cases, but further research is needed.
Area of Science:
- Immunology
- Rheumatology
- Genetics
Background:
- Behçet's disease (BD) is a complex systemic inflammatory disorder with a poorly understood pathogenesis.
- Historically classified as autoimmune, BD is now recognized at the intersection of autoimmune and autoinflammatory conditions.
Purpose of the Study:
- To explore the evolving understanding of Behçet's disease pathogenesis.
- To evaluate the role of novel therapeutic strategies targeting the interleukin-1 (IL-1) pathway in BD.
Main Methods:
- Review of current literature on BD pathogenesis and treatment.
- Analysis of clinical data regarding the use of IL-1 inhibitors (anakinra, canakinumab) in BD patients.
Main Results:
- The classification of BD has shifted towards a combined autoimmune and autoinflammatory model.
- IL-1 inhibition has demonstrated efficacy in BD patients refractory to conventional treatments, offering new therapeutic avenues.
Conclusions:
- Behçet's disease represents a unique syndrome bridging innate and adaptive immunity.
- Further investigation is crucial to elucidate immune system interactions in BD and optimize anti-IL-1 therapy (dosage, timing, and organ-specific responses).
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
717
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
717
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
606
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
606
01:29Inflammatory Bowel Disease IV: Pharmacological Management
909
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
909
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
655
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655
01:24T Cell Types and Functions
3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
602
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
602